Screener
TG Therapeutics TGTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | (2,453) | (2,733) | (3,039) | (3,141) |
| Net income | $7,781 | $28,187 | $27,558 | $33,247 |
| Net income per common share: | ||||
| Basic | $0.05 | $0.19 | $0.19 | $0.23 |
| Diluted | $0.05 | $0.17 | $0.17 | $0.20 |
| Weighted-average shares of common stock outstanding | ||||
| Basic | 141,770,283 | 146,739,833 | 143,097,453 | 146,708,980 |
| Diluted | 157,281,850 | 162,559,404 | 158,664,407 | 162,528,551 |
Document
FAQ
- What is TG Therapeutics's EPS (diluted)?
- TG Therapeutics (TGTX) reported EPS (diluted) of $0.05 in Q2 2026.
- How has TG Therapeutics's EPS (diluted) changed year-over-year?
- TG Therapeutics's EPS (diluted) decreased by 70.6% year-over-year, from $0.17 to $0.05.
- What is the long-term trend for TG Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), TG Therapeutics's EPS (diluted) has grown at a 1.9% compound annual growth rate (CAGR), from -$2.63 to $2.78.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about TG Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude